Citation Impact
Citing Papers
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
2004
Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m 6 A-demethylation of NANOG mRNA
2016 StandoutNobel
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Global patterns and trends in colorectal cancer incidence and mortality
2016 Standout
Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel
2004
Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing “Generally Recognized As Safe” (GRAS) nanopharmaceuticals: A review
2013
Enhancing effect of platelet‐derived microvesicles on the invasive potential of breast cancer cells
2006
Contribution of platelets to tumour metastasis
2011 Standout
5-HT3 Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and Vomiting
1998
Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
1999
Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial
2004
Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting
2000
A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis
2007
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Endometriosis
2009 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Biodegradable luminescent porous silicon nanoparticles for in vivo applications
2009 Standout
Management of malignant pleural mesothelioma: a critical review
2000
Metabolism and action of amino acid analog anti-cancer agents
1990
An Expanded Set of Amino Acid Analogs for the Ribosomal Translation of Unnatural Peptides
2007 StandoutNobel
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
2004
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
1995
Stimuli-responsive nanocarriers for drug delivery
2013 Standout
The Pictet–Spengler Reaction in Nature and in Organic Chemistry
2011 Standout
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Cancer stem cells revisited
2017 Standout
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Treatment of cancer in sub-Saharan Africa
2013
Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials
2004
Aromatase inhibitors: the next generation of therapeutics for endometriosis?
2006
The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders
2007 Standout
Carcinoma of the Male Breast
1992
Prognostic factors of malignant mesothelioma of the pleura
1993
Individual patient data analysis to assess modifications to the RECIST criteria
2008
External beam radiation therapy for the treatment of pleural mesothelioma
2004
Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers
2004
Global cancer statistics
2011 Standout
Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study
2008
Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion
2001
Advances in the Treatment of Malignant Pleural Mesothelioma
1999
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
1996
Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010
2011
Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer
2016
Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.
1994
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Role of anthracyclines in the era of targeted therapy
2007
Male breast cancer
2006 Standout
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
2010 Standout
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
Malignant pleural mesothelioma
1998
Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group B
1998
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab
2008
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis
2001
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Non-Hodgkin lymphoma
2012
ABC transporters in cancer: more than just drug efflux pumps
2010
Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists
1994
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
2008
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
A Review of Chemotherapy Trials for Malignant Mesothelioma
1998
A proposed new International TNM Staging System for malignant pleural mesothelioma from the International Mesothelioma Interest Group
1996
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Chronic neutrophilic leukemia and multiple myeloma: An association with λ light chain expression
1990
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Combination raltitrexed (Tomudex®)–oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma
2000
Guideline implementation for breast healthcare in low-income and middle-income countries
2008
Modes of resistance to anti-angiogenic therapy
2008 Standout
International Adaptations of NCCN Clinical Practice Guidelines in Oncology
2014
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
Preservation of Fertility in Patients with Cancer
2009 Standout
Docetaxel-related side effects and their management
2009
Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer
2010
Advances in Malignant Mesothelioma
2005 Standout
Update on tubulin-binding agents
2005
Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study
2018
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications
2015 StandoutNobel
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management.
2008
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study
1992
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study
2004
Polymer-Caged Nanobins for Synergistic Cisplatin−Doxorubicin Combination Chemotherapy
2010
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Clonality of chronic neutrophilic leukaemia associated with myeloma: analysis using the X-linked probe M27 beta.
1993
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
1999
Extending Survival with Chemotherapy in Metastatic Breast Cancer
2005
Cancer treatment and survivorship statistics, 2016
2016 Standout
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resource‐Stratified Phased Implementation: Methods and overview
2020
Silencing of tryptamine biosynthesis for production of nonnatural alkaloids in plant culture
2009
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer
2005
Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
2010 Standout
Enzymatic aminoacylation of tRNA with unnatural amino acids
2006 StandoutNobel
Global cancer statistics, 2012
2015 Standout
Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone
2001
Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis
1995
The World Health Organization (WHO) classification of the myeloid neoplasms
2002 Standout
The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
2003 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of Daniel Vorobiof being referenced
Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98
2010
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy
2006
Ondansetron Compared with Granisetron in the Prophylaxis of Cisplatin-lnduced Acute Emesis: A Multicentre Double-Blind, Randomised, Parallel-Group Study
1994
First line therapy with paclitaxel (Taxol®) and pegylated liposomal doxorubicin (Caelyx®) in patients with metastatic breast cancer: a multicentre phase II study
2004
Guideline implementation for breast healthcare in low- and middle-Income countries: Treatment resource allocation
2008
Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment
2003
Locally advanced breast cancer
2008
A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen
2009
Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-Sensitive and Partially Platinum-Sensitive Metastatic Ovarian Cancer
2009
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
1988
Nasally administered buserelin inducing complete remission of lung metastases in male breast Cancer
1987
Phase II trial of acivicin in malignant mesothelioma.
1987
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
2015
A phase II study of m-AMSA in patients with malignant mesothelioma
1983
A Randomised Comparison of Oestrogen Suppression with Anastrozole and Formestane in Postmenopausal Patients with Advanced Breast Cancer
1997
Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure
2004
Rituximab Maintenance Treatment for a Maximum of 5 Years In Follicular Lymphoma: Safety Analysis of the Randomized Phase III Trial SAKK 35/03
2010
Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial
2003
Phase 2 study of combination therapy with liposomal doxorubicin and carboplatin in patients with relapsed, platinum sensitive ovarian cancer
2004
Phase 2 study of combination therapy with liposomal doxorubicin and carboplatin in patients with relapsed, platinum sensitive ovarian cancer
2004
Chronic Granulocytic Leukemia, Neutrophilic Type, with Paraproteinemia (IgA Type K)
1978